Dimyristoylphosphatidylcholine (DMPC)

A synthetic phospholipid used in liposomes and lipid bilayers for the study of biological membranes.

Also Known As:

DMPC; 1,2-Dimyristoyl-glycero-3-phosphorylcholine; 1,2-Ditetradecanoyl-glycero-3-phosphocholine; 1,2-Ditetradecyl-glycero-3-phosphocholine; DMCP; 1,2 Dimyristoyl glycero 3 phosphorylcholine; 1,2 Ditetradecanoyl glycero 3 phosphocholine; 1,2 Ditetradecyl glycero 3 phosphocholine; Dimyristoyllecithin; 3,5,9-Trioxa-4-phosphatricosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-((1-oxotetradecyl)oxy)-, inner salt, 4-oxide

Networked: 149 relevant articles (7 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Lipids: 114793
- Membrane Lipids: 1591
  - Phospholipids: 11903
    - Glycerophosphates: 118
      - Phosphatidic Acids: 358
        Glycerophospholipids: 689
        Phosphatidylcholines: 2371
        Dimyristoylphosphatidylcholine: 149
        dimyristoylphosphatidylsulfocholine: 1
        1,2-bis(12-methoxydodecanoyl)-sn-glycero-3-phosphocholine
        1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine
        1-(myristoyl)-2-(7,7-difluoromyristoyl)glycero-3-phosphocholine

Experts

1.	Matsumoto, Yoko: 28 articles (03/2021 - 04/2002)
2.	Ueoka, Ryuichi: 27 articles (01/2016 - 04/2002)
3.	Ichihara, Hideaki: 17 articles (11/2020 - 01/2003)
4.	Komizu, Yuji: 10 articles (01/2016 - 12/2006)
5.	Goto, Koichi: 9 articles (06/2013 - 04/2002)
6.	Hino, Motoki: 4 articles (07/2015 - 01/2011)
7.	Kuwabara, Keiji: 3 articles (11/2020 - 01/2016)
8.	Matsushita, Taku: 3 articles (07/2010 - 06/2005)
9.	Iwamoto, Yasunori: 3 articles (06/2005 - 11/2002)
10.	Matyszewska, Dorota: 2 articles (03/2022 - 02/2016)

Related Diseases

1.	Neoplasms (Cancer) 02/01/2023 - "We searched the Surveillance, Epidemiology and End Results Database for cases of DMPC diagnosed between 2004 and 2019, analyzed their clinical characteristics and the cancer-specific survival (CSS) rates relating to different factors using the Kaplan-Meier method and the differences among the variables by log-rank test. " 10/01/2015 - "The DSPC formulation displayed the highest drug accumulation in the tumor with 2-fold, 3-fold and 100-fold increases compared to DPPC, DMPC and free CDDP respectively. " 11/01/2012 - "GC patients with DMPC had a significantly higher age (p <0.0001) and higher incidence of differentiated cancer(p=0.0045) than those without DMPC. " 05/08/2009 - "To evaluate the in vivo capability of 1-MTX to radiosensitize tumors, we developed temperature-sensitive liposomal 1-MTX using DPPC:DMPC:DSPC (4:1:1 molar ratio) with intention of overcoming lethal toxicity of 1-MTX and controlling drug-release. " 10/01/2015 - "These results suggest that the DSPC liposomal formulation is a promising formulation for MDR tumor therapy over DMPC and DPPC formulations and free drug."
2.	Neoplasm Metastasis (Metastasis) 01/01/2011 - "Furthermore, prolonged survival was obtained in the hepatic metastasis mouse models after the treatment with DMPC/DHA. " 01/01/2011 - "The histological analysis indicated the induction of apoptosis was observed in the liver section of the hepatic metastasis mouse models treated with DMPC/DHA in vivo. " 01/01/2011 - "Therapeutic effects of DMPC/DHA without any drugs on the hepatic metastasis were revealed on the basis of histological and biochemical analyses for the first time in vivo." 01/01/2011 - "Remarkably high therapeutic effects were obtained in the hepatic metastasis mouse models of HCT116 cells after the intravenous injection of DMPC/DHA. " 01/01/1987 - "These studies suggest that MLV composed of DMPC and DMPG containing NDDP are able to cross the liver sinusoidal capillaries and gain access to both hepatocytes from normal liver and malignant cells of M5076 reticulosarcoma from liver metastases."
3.	Breast Neoplasms (Breast Cancer) 08/01/2012 - "DMpC therapy appears to have few side effects and might be an effective treatment option for recurrent breast cancer patients with a poor general health condition." 05/01/2005 - "DMpC therapy could thus be one the most useful treatments for advanced breast cancer." 03/01/2002 - "[Successful treatment of advanced recurent breast cancer using DMpC therapy as maintenance therapy]." 12/01/2008 - "Oral anti-cancer treatments such as DMpC appear to have few side effects and might be an effective treatment option for recurrent breast cancer patients with triple negative disease." 05/01/2005 - "[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)]."
4.	Glioma (Gliomas) 05/01/2010 - "In addition, treatment of Ad in the PL state showed enhanced green fluorescent protein (GFP) expression when compared with treatment with Ad alone or with DMPC-Ad in hepatoma and brain glioma cells. " 12/04/2000 - "Three-component hybrid liposomes composed of L-alpha-dimyristoylphosphatidylcholine, micellar surfactant (Tween 20), and beta-D-fructofuranosyl-alpha-D-glucopyranoside monododecanoate were found to be highly effective for inhibiting the growth of glioma cells without any drug." 04/01/2002 - "It is noteworthy that high inhibitory effects of the three-component hybrid liposomes composed of DMPC, Tween 20, and LacCn (DMPC:Tween 20:LacCn=65:7:28) on the growth of glioma (U251) and lung adenocarcinoma (RERF-LC-OK) cells were attained in vitro without any drug, although no significant inhibitory effects of any individual component (DMPC, Tween 20, LacCn) or the two-component hybrid liposomes of DMPC and Tween 20 on the growth of tumor cells examined were obtained." 02/01/2010 - "Liposomes formulated with dimyristoyl-sn-glycero-phosphatidylcholine, DMPC, and either one of the cationic gemini surfactants (S,S)-2,3-dimethoxy-1,4-bis(N-hexadecyl-N,N-dimethylammonio)butane bromide, 1a, and (S,R)-2,3-dimethoxy-1,4-bis(N-hexadecyl-N,N-dimethylammonio)butane bromide, 1b, were investigated as vehicles of the photosensitizer m-tetrahydroxyphenylchlorin, m-THPC, to cell models of malignant glioma. " 03/01/2007 - "In this study we investigated the feasibility of mixed liposomes formed by dimyristoyl-sn-glycero-phosphatidylcholine (DMPC) and cationic gemini surfactant (Gemini 1) loaded with the chlorin m-tetrahydroxyphenylchlorin (m-THPC), in photodynamic therapy (PDT) for glioma. "
5.	Dry Eye Syndromes (Dry Eye Syndrome) 01/01/2023 - "The goals of this study were to evaluate the safety and efficacy of an ophthalmic 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)-based nanoemulsion (Nanodrop®) in patients with dry eye disease (DED). " 01/01/2023 - "Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial." 01/01/2022 - "DMPC-NE is a highly stable formulation for dry eye that is safe to be used while wearing soft CL." 01/01/2022 - "Physicochemical characterization of a DMPC-based nanoemulsion for dry eye and compatibility test with soft contact lenses in vitro."

Related Drugs and Biologics

1.	Liposomes (Liposome)
2.	Medroxyprogesterone Acetate (Depo-Provera)
3.	Cyclophosphamide (Cytoxan)
4.	doxifluridine
5.	dimyristoylphosphatidylglycerol (DMPG)
6.	Surface-Active Agents (Surfactants)
7.	Micelles
8.	Polysorbates (PSML)
9.	Dimyristoylphosphatidylcholine (DMPC)
10.	Lipids

Related Therapies and Procedures

1.	Therapeutics
2.	Photochemotherapy (Photodynamic Therapy)
3.	Lasers (Laser)
4.	Intravenous Injections
5.	Intravenous Infusions